Discussion

Michael Silver, Rachel Forfar, Philip Kemp, Carolina Fernandes, Lone Friis,
David Matthews, Andy Merritt and Jonathan Large

MRC Technology, Centre for Therapeutics Discovery, 1-3 Burtonhole Lane, Mill Hill, London, NW7 1AD

Antibody drug conjugation (ADC) is an innovative platform for the treatment of cancer, which combines the targeting properties of antibodies with potent, cytotoxic small molecules. Recent reports have revealed that CRLF2 is a cell surface receptor which is overexpressed in approximately 5% of cases of B-Cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL). This poster will describe our work with in-house generated, high-affinity antibodies to CRLF2, which has focussed on assessing their potential use in an antibody drug conjugation approach. We will show key cell binding and internalisation data generated by employing flow cytometry and fluorescently labelled mAbs, along with recent work involving the use of cytotoxic secondary antibodies.